{
    "id": 27509,
    "fullName": "NTRK1 F646I",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NTRK1 F646I lies within the protein kinase domain of the Ntrk1 protein (UniProt.org). F646I has been demonstrated to confer resistance to Ntrk inhibitors as a secondary resistance mutation in the context of TPM3-NTRK1 (PMID: 28751539), but has not been biochemically characterized and therefore, its effect on Ntrk1 protein function is unknown (PubMed, Nov 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4914,
        "geneSymbol": "NTRK1",
        "terms": [
            "NTRK1",
            "MTC",
            "p140-TrkA",
            "TRK",
            "Trk-A",
            "TRK1",
            "TRKA"
        ]
    },
    "variant": "F646I",
    "createDate": "03/15/2018",
    "updateDate": "11/03/2019",
    "referenceTranscriptCoordinates": {
        "id": 112550,
        "transcript": "NM_002529",
        "gDna": "chr1:g.156879252T>A",
        "cDna": "c.1936T>A",
        "protein": "p.F646I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13178,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing TPM3-NTRK1 and NTRK1 F646I were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 28751539).",
            "molecularProfile": {
                "id": 29022,
                "profileName": "TPM3 - NTRK1 NTRK1 F646I"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13175,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing TPM3-NTRK1 and NTRK1 L564H were resistant to Foretinib (GSK1363089) in culture (PMID: 28751539).",
            "molecularProfile": {
                "id": 29022,
                "profileName": "TPM3 - NTRK1 NTRK1 F646I"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13176,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing TPM3-NTRK1 and NTRK1 F646I were sensitive to Iclusig (ponatinib) in culture, demonstrating growth inhibition (PMID: 28751539).",
            "molecularProfile": {
                "id": 29022,
                "profileName": "TPM3 - NTRK1 NTRK1 F646I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10995,
                    "pubMedId": 28751539,
                    "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20641,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing TPM3-NTRK1 and NTRK1 F646I were sensitive to treatment with DS6051b in culture, demonstrating cell growth inhibition (PMID: 31399568).",
            "molecularProfile": {
                "id": 29022,
                "profileName": "TPM3 - NTRK1 NTRK1 F646I"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29021,
            "profileName": "NTRK1 F646I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29022,
            "profileName": "TPM3 - NTRK1 NTRK1 F646I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 112550,
            "transcript": "NM_002529",
            "gDna": "chr1:g.156879252T>A",
            "cDna": "c.1936T>A",
            "protein": "p.F646I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}